Company Overview
About PostEra
PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.
Business Model & Competitive Advantage
PostEra's Proton AI platform addresses the medicinal chemistry design bottleneck in drug discovery: identifying a promising drug target (a protein or biological mechanism involved in disease) is the starting point, but optimizing a small molecule drug candidate from initial hit to clinical candidate requires designing hundreds of molecular variants that systematically improve potency, selectivity, metabolic stability, and drug-likeness while maintaining synthesizability — a chemistry design-make-test cycle that takes medicinal chemistry teams 2-4 years of iterative laboratory work. PostEra's ML models (trained on synthesis pathway data and structure-activity relationship datasets) generate molecular designs that are both biologically optimized for the target and practically synthesizable by chemistry teams — reducing the design-to-synthesis cycle by predicting which molecular modifications will improve properties without creating unsynthesizable structures. The ADC design capability (predicting optimal drug-linker-antibody conjugation sites and payload chemistry for homogeneous ADC drug-to-antibody ratios) addresses the hottest growth area in oncology drug development.
Competitive Landscape 2025–2026
In 2025, PostEra competes in the AI drug discovery, computational chemistry, and medicinal chemistry AI market with Schrödinger (NASDAQ: SDGR, physics-based drug design software, $1.5B raised), Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery, $800M raised), and Insilico Medicine (AI drug discovery, $400M raised) for pharmaceutical company AI-accelerated medicinal chemistry and lead optimization adoption. The $610M Pfizer collaboration expansion (January 2025) represents one of the largest AI drug discovery partnership expansions in 2025 and validates PostEra's commercial model of technology licensing plus milestone economics for pharma partnerships. The 40% faster preclinical milestone achievement demonstrates the AI acceleration value proposition at the most risk-intensive stage of pharmaceutical development. The 2025 strategy focuses on expanding the Pfizer and Amgen program scope, signing additional top-10 pharma collaborations for new therapeutic areas, and building the ADC design platform for the oncology ADC market.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
PostEra is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $1000M in revenue, PostEra operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Compare PostEra with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from PostEra? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim PostEra Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention PostEra vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →